

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

Afrezza (insulin human) inhalation

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Package Description	Quantity Limit
Afrezza (insulin human) inhalation	90 cartridges (4 unit)	6 boxes per 30 days
	90 cartridges (8 unit)	4 boxes per 30 days
	90 cartridges (12 unit)	3 boxes per 30 days
	90 cartridges (60x4 unit and 30x8 unit)	6 boxes per 30 days
	90 cartridges (30x4 unit and 60x8 unit)	5 boxes per 30 days
	90 cartridges (60x8 unit and 30x12 unit)	4 boxes per 30 days
	180 cartridges (90x4 unit and 90x8 unit)	3 boxes per 30 days
	180 cartridges (60x4 unit and 60x8 unit and 60x12 unit)	2 boxes per 30 days

APPROVAL CRITERIA

Requests for Afrezza (insulin human) may be approved if the following criteria are met (either I, II) AND (III, IV and V):

- I. Individual has had a previous trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of one preferred rapid-acting insulin (Admelog);
OR
- II. Individual is requesting Afrezza and is unable or unwilling to administer injectable insulin.

AND

- III. Individual is 18 years of age or older; **AND**
- IV. Individual has a diagnosis of diabetes mellitus and one of the following:
 - A. For type 1 diabetes, individual will be using concurrently with long-acting insulin;
OR
 - B. For type 2 diabetes, individual has inadequate control, intolerance, or contraindication to at least 2 oral anti-diabetic medications;

AND

- V. Individual has had a physical examination including detailed medical history to identify potential lung disease.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

*FHK- Florida Healthy Kids

Afrezza (insulin human) **may not** be approved for the following:

- I. Individuals with a diagnosis of chronic lung disease, such as asthma or chronic obstructive pulmonary disease; **OR**
- II. Individuals who smoke cigarettes or who recently (within 6 months) quit smoking; **OR**
- III. As a treatment for diabetic ketoacidosis.

Note: Afrezza (insulin human) has a black box warning for the risk of acute bronchospasm in individuals with chronic lung disease. Afrezza is contraindicated in individuals with chronic lung disease such as asthma or COPD. Acute bronchospasm has been observed in these individuals. Before initiating therapy, a detailed medical history, physical exam, and spirometry (FEV1) should be performed to identify potential lung disease.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2016. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2016; Updated periodically.